Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720812 | 0.92 | SIGMAR1 (0.85) | SIGMAR1 | |
| SCHEMBL6727463 | 0.92 | SIGMAR1 (0.85) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6724568 | 0.87 | SIGMAR1 (0.77) | SIGMAR1 | |
| SCHEMBL8497150 | 0.86 | SIGMAR1 (0.75) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL8194426 | 0.86 | SIGMAR1 (0.75) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL7647490 | 0.86 | SIGMAR1 (0.78) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6717192 | 0.85 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL6721184 | 0.85 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL6721400 | 0.84 | SIGMAR1 (0.72) | SIGMAR1 | |
| SCHEMBL6720759 | 0.82 | SIGMAR1 (0.69) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | claimed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| EP-0517852-B1 | TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | OREGON STATE (US) | 2002-07-10 | — | — | EP | claimed |
| JP-3298875-B2 | — | — | 2002-07-08 | — | — | JP | claimed |
| US-6251948-B1 | Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON | 2001-06-26 | — | — | US | claimed |
| US-6242198-B1 | ADMINISTERING GUANIDINE COMPOUND | CAMBRIDGE NEUROSCIENCE, INC. | 2001-06-05 | — | — | US | claimed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | claimed |
| US-5798390-A | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-08-25 | — | — | US | claimed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| US-5559154-A | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists | OREGON STATE BOARD OF HIGHER EDUCATION | 1996-09-24 | — | — | US | claimed |
| US-5336689-A | Treating diseases of the nervous system; neuroprotective | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1994-08-09 | — | — | US | claimed |
| EP-0517852-A4 | — | — | 1994-03-02 | — | — | EP | claimed |
| US-5262568-A | Neuroprotective compounds, high binding affinity for phencyclidine, nervous system disorders | STATE OF OREGON (US) | 1993-11-16 | — | — | US | claimed |
| EP-0517852-A1 | TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1992-12-16 | — | — | EP | claimed |
| WO-1991012797-A1 | TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALF SCIENCES UNIVERSITY (US) | 1991-09-05 | — | — | WO | claimed |
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1991012797-A1 | TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALF SCIENCES UNIVERSITY (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | SIGMAR1 3775/4885TP53 4568/4885CYP2D6 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.